Nitroxoline is under clinical development by Asieris Pharmaceuticals and currently in Phase II for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer). According to GlobalData, Phase II drugs for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Nitroxoline’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Nitroxoline overview

Nitroxoline is under development for the treatment of muscle invasive bladder cancer (MIBC), non-muscle invasive bladder cancer (NMIBC) and prostate cancer. The drug candidate is formulated as tablet and administered orally. It is a repurposed urinary antibiotic and targets methionine aminopeptidase type 2 (METAP2).

Asieris Pharmaceuticals overview

Asieris Pharmaceuticals discovers and develops drugs for the treatment of genitourinary tumors. The company is investigating APL-1202, an oral drug to treat non-muscle-invasive bladder cancer (NMIBC); APL-1702(Cevira), a photodynamic therapy against cervical high grade squamous intraepithelial lesion (HSIL); and APL-1706 (Hexvix), a fluorescent imaging agent to assist in the diagnosis of bladder cancer. It is also evaluating drugs for triple negative breast cancer, metastatic castration resistant prostate cancer, ER positive breast cancer and other reproductive diseases; autoimmune diseases; and Acinetobacter baumannii infection. Asieris Pharmaceuticals conducts research and development in the therapeutic areas of bladder cancer, oncology, multidrug-resistance infections and tumor immunotherapy. The company operates with additional offices in the US and China. Asieris Pharmaceuticals is headquartered in Pudong, China.

For a complete picture of Nitroxoline’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.